Geoffrey S. Dow Buys 17,549 Shares of 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) Stock

60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) CEO Geoffrey S. Dow acquired 17,549 shares of the stock in a transaction on Thursday, December 5th. The stock was bought at an average price of $1.11 per share, for a total transaction of $19,479.39. Following the transaction, the chief executive officer now owns 38,178 shares in the company, valued at approximately $42,377.58. This represents a 85.07 % increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink.

60 Degrees Pharmaceuticals Stock Up 26.1 %

Shares of SXTP stock traded up $0.30 during mid-day trading on Monday, hitting $1.45. 271,120 shares of the stock were exchanged, compared to its average volume of 237,634. 60 Degrees Pharmaceuticals, Inc. has a 52-week low of $0.70 and a 52-week high of $18.36. The company has a market cap of $3.34 million, a PE ratio of -0.14 and a beta of 5.36. The firm has a fifty day moving average of $0.99 and a 200 day moving average of $0.81.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a report on Friday, November 15th.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.